FDA approves Alnylam’s ultra-rare disease drug Oxlumo
pharmaphorum
NOVEMBER 24, 2020
Alnylam’s Givlaari, FDA-approved a year ago for acute hepatic porphyria, costs $575,000 per year at full price in the US, although after discounts the figure is more likely to be in the region of $442,000 per year. Alnylam licensed inclisiran to The Medicines Company, which was bought last year by Novartis for $9.7
Let's personalize your content